End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
56.2 TWD | +1.81% | +3.69% | -18.90% |
Mar. 20 | CHO Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | CHO Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Sales 2022 | 60K 1.86K | Sales 2023 | - | Capitalization | 14.83B 460M |
---|---|---|---|---|---|
Net income 2022 | -338M -10.49M | Net income 2023 | -306M -9.5M | EV / Sales 2022 | 402,853 x |
Net cash position 2022 | 1.03B 32.05M | Net cash position 2023 | 2.6B 80.77M | EV / Sales 2023 | - |
P/E ratio 2022 |
-74.5
x | P/E ratio 2023 |
-43.3
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
1 day | +1.81% | ||
1 week | +3.69% | ||
Current month | +3.12% | ||
1 month | +3.50% | ||
3 months | -7.87% | ||
6 months | -20.51% | ||
Current year | -18.90% |
Managers | Title | Age | Since |
---|---|---|---|
Tsung I Wu
CEO | Chief Executive Officer | - | - |
Chao-Long Chen
CHM | Chairman | - | 17-12-26 |
Yi Pei Chou
DFI | Director of Finance/CFO | - | 16-03-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ming Hsing Tsai
BRD | Director/Board Member | 67 | 13-05-26 |
Hsuan Ta Liu
BRD | Director/Board Member | - | 19-06-05 |
Chao-Long Chen
CHM | Chairman | - | 17-12-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 114 M€ | +5.60% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 56.2 | +1.81% | 269,082 |
24-06-11 | 55.2 | +0.36% | 199,140 |
24-06-07 | 55 | -0.54% | 210,059 |
24-06-06 | 55.3 | -3.32% | 456,012 |
24-06-05 | 57.2 | +5.54% | 886,936 |
End-of-day quote Taipei Exchange, June 11, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-18.90% | 364M | |
-1.54% | 91.26B | |
-2.37% | 38.17B | |
+71.42% | 26.74B | |
-12.31% | 15.93B | |
-4.54% | 13.37B | |
-10.83% | 11.77B | |
+180.20% | 10.92B | |
-48.60% | 10.27B | |
+1.42% | 8.69B |
- Stock Market
- Equities
- 6586 Stock